Translating scientific discoveries into affordable,
globally accessible public health solutions


What We Do


new approaches to developing vaccines and other means of preventing HIV.


translational and clinical research through our laboratories in the U.S., India, and the U.K.

Build Capacity

in-country for researching vaccine candidates while strengthening local public health and scientific expertise.


with industry and enlist biopharma product development skills to develop innovative products tailored to target populations.


IAVI’s resources with other innovators to help the HIV community as a whole succeed.


IAVI’s core capabilities to solving disease prevention and treatment challenges.

Latest News from IAVI

Girl playing in doorway in India

IAVI, University of Oslo, & THSTI to Partner for HIV Prevention R&D

Technology transfer and international cooperation could lead to long-lived HIV protection for women and girls in developing countries

Donor Spotlight: The Norwegian Government

IAVI recognizes the Norwegian government and its Norwegian Development Agency (Norad) for its continued commitment to HIV vaccine research and applauds its dedication to global health research and development.

Black mamba

IAVI Partners in Snakebite Treatment Consortium

Partners in five countries will discover and develop monoclonal antibodies to treat critical illness from snake venom, which harms nearly 3 million people each year.

IAVI Report: Special issue on HIV vaccine science in Africa, for Africa

The issue was inspired by the elegant science being produced by scientists in Africa and the scientific capacity being built via IAVI’s ADVANCE program.

Vaccine being given in arm

Phase I Trial of Native-like HIV Env Trimer

Phase I Trial to Evaluate Safety and Immunogenicity of Engineered Envelope Protein

The Need for Long-Acting HIV Prevention

Women living in Kenya and South Africa describe the cultural and economic barriers to HIV prevention.



Kenya HIV & AIDS Research Agenda